Can-Fite Shares Rise After Pancreatic Cancer Study Meets Target
MT Newswires Live
Mar 04
Can-Fite BioPharma (CANF) shares were up over 90% in recent Wednesday trading after the company said its phase 2a study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.
The study, which enrolled 20 patients who had received one or more prior lines of therapy, showed that namodenoson was very well tolerated, and no new safety signals were identified, it said.
Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.